ArriVent BioPharma, Inc. AVBP Drug Firmonertinib — Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about ArriVent BioPharma, Inc.'s drug firmonertinib — research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ArriVent BioPharma, Inc.'s drug firmonertinib — research and development expense?
- ArriVent BioPharma, Inc. (AVBP) reported drug firmonertinib — research and development expense of $15.08M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s drug firmonertinib — research and development expense changed year-over-year?
- ArriVent BioPharma, Inc.'s drug firmonertinib — research and development expense increased by 5.4% year-over-year, from $14.3M to $15.08M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s drug firmonertinib — research and development expense?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s drug firmonertinib — research and development expense has grown at a 15.7% compound annual growth rate (CAGR), from $50.48M to $67.61M.
- What does drug firmonertinib — research and development expense mean?
- This metric measures the total direct research and development expenditures dedicated to the advancement of a specific drug candidate through its clinical and regulatory lifecycle. It encompasses costs related to clinical trials, manufacturing process development, and regulatory filings required to bring the therapeutic to market. Monitoring this expense provides insight into the company's commitment to the asset's development and the intensity of the clinical program's progress.